Mathematical and computational models of drug transport in tumours

The ability to predict how far a drug will penetrate into the tumour microenvironment within its pharmacokinetic (PK) lifespan would provide valuable information about therapeutic response. As the PK profile is directly related to the route and schedule of drug administration, an in silico tool that can predict the drug administration schedule that results in optimal drug delivery to tumours would streamline clinical trial design. This paper investigates the application of mathematical and computational modelling techniques to help improve our understanding of the fundamental mechanisms underlying drug delivery, and compares the performance of a simple model with more complex approaches. Three models of drug transport are developed, all based on the same drug binding model and parametrized by bespoke in vitro experiments. Their predictions, compared for a ‘tumour cord’ geometry, are qualitatively and quantitatively similar. We assess the effect of varying the PK profile of the supplied drug, and the binding affinity of the drug to tumour cells, on the concentration of drug reaching cells and the accumulated exposure of cells to drug at arbitrary distances from a supplying blood vessel. This is a contribution towards developing a useful drug transport modelling tool for informing strategies for the treatment of tumour cells which are ‘pharmacokinetically resistant’ to chemotherapeutic strategies.

[1]  J. Brown,et al.  Solid-phase extraction and optimized separation of doxorubicin, epirubicin and their metabolites using reversed-phase high-performance liquid chromatography. , 1992, Journal of pharmaceutical and biomedical analysis.

[2]  John R. Wolberg,et al.  Data Analysis Using the Method of Least Squares: Extracting the Most Information from Experiments , 2005 .

[3]  Alexander G. Fletcher,et al.  Chaste: A test-driven approach to software development for biological modelling , 2009, Comput. Phys. Commun..

[4]  T. Waldman,et al.  PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells , 2004, Cancer Research.

[5]  J. Lankelma,et al.  A mathematical model of drug transport in human breast cancer. , 2000, Microvascular research.

[6]  T. Secomb,et al.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. , 2005, Neoplasia.

[7]  M. J. Chapman,et al.  A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. , 2004, Mathematical biosciences.

[8]  J. Moore,et al.  Tumour cords in 52 human bronchial and cervical squamous cell carcinomas: inferences for their cellular kinetics and radiobiology. , 1985, British Journal of Cancer.

[9]  D. S. Jones,et al.  Differential Equations and Mathematical Biology , 1983 .

[10]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[11]  Nicholas J. Higham,et al.  Matlab guide , 2000 .

[12]  Daniela Thorwarth,et al.  Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps , 2011, Physics in medicine and biology.

[13]  S. Eikenberry Theoretical Biology and Medical Modelling Open Access a Tumor Cord Model for Doxorubicin Delivery and Dose Optimization in Solid Tumors , 2022 .

[14]  E. Rofstad,et al.  Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrast‐enhanced MRI , 2007, Journal of magnetic resonance imaging : JMRI.

[15]  H. Pohjanpalo System identifiability based on the power series expansion of the solution , 1978 .

[16]  J. Double,et al.  A critical appraisal of the predictive value of in vitro chemosensitivity assays. , 1990, Journal of the National Cancer Institute.

[17]  Peter M. A. Sloot,et al.  Modelling and Simulation , 1988, Systems Analysis and Simulation 1988, I: Theory and Foundations. Proceedings of the International Symposium held in Berlin (GDR), September 12–16, 1988.

[18]  P K Maini,et al.  A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results , 2005, Bulletin of mathematical biology.

[19]  J. Jenkins,et al.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. , 1983, Cancer research.

[20]  J. Winter,et al.  Flow cytometric assessment of the cellular pharmacokinetics of fluorescent drugs. , 1995, Cytometry.

[21]  Helen M. Byrne,et al.  A Multiple Scale Model for Tumor Growth , 2005, Multiscale Model. Simul..

[22]  J. Murray,et al.  Quantifying Efficacy of Chemotherapy of Brain Tumors with Homogeneous and Heterogeneous Drug Delivery , 2002, Acta biotheoretica.

[23]  C. Haanen,et al.  Clinical Pharmacokinetics of Doxorubicin , 1988, Clinical pharmacokinetics.

[24]  Trachette L. Jackson,et al.  Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. , 2003, Journal of theoretical biology.

[25]  R. Pletcher,et al.  Computational Fluid Mechanics and Heat Transfer. By D. A ANDERSON, J. C. TANNEHILL and R. H. PLETCHER. Hemisphere, 1984. 599 pp. $39.95. , 1986, Journal of Fluid Mechanics.

[26]  T. Secomb,et al.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. , 2000, Neoplasia.

[27]  Ralph Weissleder,et al.  A Systems Approach for Tumor Pharmacokinetics , 2011, PloS one.

[28]  C. Stokes,et al.  Effects of cellular pharmacology on drug distribution in tissues. , 1995, Biophysical journal.

[29]  B Hoerni,et al.  Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. , 1982, European journal of cancer & clinical oncology.

[30]  Xiaohua Xia,et al.  On Identifiability of Nonlinear ODE Models and Applications in Viral Dynamics , 2011, SIAM Rev..

[31]  L. Trefethen Spectral Methods in MATLAB , 2000 .

[32]  Peter Vaupel,et al.  Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. , 2008, The oncologist.

[33]  A. Waites,et al.  Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? , 1998, Advances in enzyme regulation.

[34]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[35]  Neil D. Evans,et al.  The input-output relationship approach to structural identifiability analysis , 2013, Comput. Methods Programs Biomed..

[36]  Timothy W Secomb,et al.  A mathematical model for cisplatin cellular pharmacodynamics. , 2003, Neoplasia.

[37]  S. Piscitelli,et al.  Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer , 1993, Clinical pharmacology and therapeutics.

[38]  Rebecca J. Shipley,et al.  Multiscale Modelling of Fluid and Drug Transport in Vascular Tumours , 2010, Bulletin of mathematical biology.

[39]  M. Hiraoka,et al.  Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors. , 2008, Biochemical and biophysical research communications.

[40]  Vanessa Hertzog,et al.  Computational Fluid Mechanics And Heat Transfer , 2016 .

[41]  K. Fujimori,et al.  Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.

[42]  S W Smye,et al.  A mathematical model of doxorubicin penetration through multicellular layers. , 2009, Journal of theoretical biology.

[43]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.